Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
GlaxoSmithKline (GSK), like many others in the biopharmaceutical sector, has embraced the power of genetics to identify possible new drug targets. But when its data point to proteins that haven’t been worked on before — often in unexplored families of proteins — the company’s medicinal chemists face the industry-wide challenge of quickly finding small-molecule tools to explore that biology. For Jacob Bush, Group Leader of Chemical Biology at GSK, fragment-based approaches are increasingly a possible solution.